VPM1002 is a frontrunner tuberculosis (TB) vaccine candidate.

Did you know that the 100-year-old BCG is the only vaccine available to protect against TB, and the world urgently needs a better TB vaccine?

There are several vaccine candidates in the pipeline, and our VPM1002 is one of the most advanced ones. The Scientist reported about the latest updates in the TB vaccine development. Click here to read the full article.


Recruitment has started at all clinical centers

We are pleased to announce that all clinical trial centers, located in Kenya, Tanzania, Uganda, South Africa and Gabon, have started their recruitment and are actively enrolling participants into the pivotal phase III trial (priMe) of the novel tuberculosis vaccine VPM1002.


Update on priMe study

TB vaccine candidate being investigated to prevent TB infection in infants in Phase III priMe study. Read more!


Tdap study enters phase III

Following the successful completion of phase II part of the Tdap study (tetanus, diphtheria and pertussis) Tadeus, phase III part will commence this week,